口服避孕药停用后肝细胞腺瘤的长期MRI监测与消退时间
本回顾性研究纳入116例患者共269个肝细胞腺瘤,中位MRI随访6.5年。持续保守管理的174个病灶中95.4%稳定或缩小;停用口服避孕药后,直径缩小≥10%、≥20%、≥30%的中位时间分别为8.6、24.3、49.9个月,提示消退缓慢,早期缩小有限不应单独视为保守治疗失败。
要点
- 保守管理的肝细胞腺瘤多数长期稳定或缩小,恶性转化罕见且见于β-catenin激活型。
- 停用口服避孕药后病灶消退缓慢,≥30%缩小中位时间约49.9个月。
- 早期(1年内)缩小幅度有限不应单独判定为保守治疗失败。
核心结论
- 在选择的监测队列中,多数未干预的肝细胞腺瘤长期MRI随访保持稳定或缩小。
- 停用口服避孕药后病灶消退渐进,早期可见 modest 缩小,较大幅度缩小常需数年。
- ≥5 cm亚组探索性结果显示均稳定或消退,64.7%末次影像低于5 cm。
研究设计与样本
- 共116例患者(110例女性,平均年龄38±10岁),269个肝细胞腺瘤,中位随访6.5年。
- 每个患者最多追踪3个索引病灶,采用基于RECIST 1.1的预设病灶水平大小变化阈值分类。
- 在记录停用口服避孕药后的病灶中,用Kaplan-Meier法估计直径缩小≥10%、≥20%、≥30%的时间。
- 进行每患者最大病灶的敏感性分析。
关键影像表现/征象
- 持续保守管理的174个病灶中,166个(95.4%)稳定或消退。
- 基线直径≥5 cm的17个病灶亚组中,全部稳定或消退,11个(64.7%)末次影像低于5 cm。
- 停用口服避孕药后的81个病灶,直径缩小≥10%、≥20%、≥30%的中位时间分别为8.6、24.3、49.9个月(≥30%的95%CI 36.2-75.1)。
- 两例恶性转化均发生于β-catenin激活型肝细胞腺瘤,监测期间无出血事件。
诊断标准与关键数值
- 病灶大小变化阈值基于RECIST 1.1惯例预设,用于分类稳定、消退或进展。
- 停用口服避孕药后病灶消退时间以Kaplan-Meier法估计,直径缩小≥10%、≥20%、≥30%的中位时间分别为8.6、24.3、49.9个月。
临床应用与阅片要点
- 对选择保守管理的肝细胞腺瘤,长期MRI监测中多数病灶稳定或缩小,可支持继续保守策略。
- 停用口服避孕药后应预期消退缓慢,早期缩小幅度有限(如<10%)不应单独解读为治疗失败。
- 对≥5 cm病灶,探索性数据显示多数可稳定或消退至<5 cm,但仍需个体化监测。
- β-catenin激活型肝细胞腺瘤恶性转化风险较高,监测中需关注。
局限性
- 回顾性研究设计。
- ≥5 cm亚组样本量小(17个病灶),结果为探索性。
- 单中心研究,选择偏倚可能影响结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To describe the long-term MRI evolution of hepatocellular adenomas (HCAs) selected for conservative management and to quantify the time to predefined degrees of lesion size reduction after oral contraceptive pill (OCP) cessation.
METHODS: In this retrospective study, adults with pathologically proven or imaging-typical HCA who underwent serial liver MRI between January 2010 and December 2024 were reviewed. Up to three indexed lesions per patient were tracked, and lesion evolution was categorized using predefined lesion-level size-change thresholds derived from RECIST 1.1 conventions. In lesions from patients with documented post-diagnosis OCP cessation, time to ≥ 10%, ≥ 20%, and ≥ 30% diameter reduction was estimated using Kaplan-Meier analysis. Primary outcomes were repeated in one-lesion-per-patient sensitivity analyses (largest lesion per patient).
RESULTS: 116 patients (110 women; mean age 38 ± 10 years) with 269 HCAs; median follow-up 6.5 years. Among 174 lesions selected for continued conservative management, 166 (95.4%) were stable or regressed. In an exploratory subgroup of 17 lesions with baseline diameter ≥ 5 cm, all were stable or regressive and 11 (64.7%) measured below 5 cm at last imaging. Among 81 lesions after OCP cessation, median times to ≥ 10%, ≥ 20%, and ≥ 30% diameter reduction were 8.6, 24.3, and 49.9 months (95% CI for ≥ 30%, 36.2-75.1). Findings were similar in sensitivity analyses. Both observed malignant transformations occurred in β-catenin-activated HCA, with no surveillance hemorrhage.
CONCLUSION: In this selected surveillance cohort, most HCAs managed without intervention remained stable or decreased in size during long-term MRI follow-up. After OCP cessation, regression was gradual, with modest reduction often apparent within the first year but larger reductions frequently requiring several years; findings in the small ≥ 5 cm subgroup were exploratory. Limited early size reduction should therefore not, in isolation, be interpreted as failure of conservative management.
引用
- Jain N, Kim TK, Khalili K, et al. Long-term MRI surveillance of hepatocellular adenomas selected for conservative management: time to regression after oral contraceptive cessation. Abdom Radiol (NY). 2026. PMID: 42961643. doi:10.1007/s00261-026-05845-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。